Navigation Links
Genomic Health to Present at Two Upcoming Investor Conferences
Date:5/27/2011

REDWOOD CITY, Calif., May 27, 2011 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that members of its management team will present at the following conferences in June:

  • Brad Cole, Genomic Health's Chief Operating Officer, will present at the Jefferies 2011 Global Healthcare Conference on Monday, June 6 at 3:30 p.m. ET in New York City; and
  • Kim Popovits, Genomic Health's President and Chief Executive Officer, and Dean Schorno, Genomic Health's Chief Financial Officer, will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7 at 3:20 p.m. PT in Palos Verdes, Calif.

To access the live and subsequently archived webcasts of the presentations, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads. An archived replay will be available for three months beginning 24 hours after the live presentations.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.  Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer.  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease.  As of March 31, 2011, more than 10,000 physicians in over 60 countries had ordered more than 200,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional stages of breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline, the ability of the company to develop additional tests in the future, and the ability of any potential tests the company may develop to optimize cancer treatment. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests;  the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly  Report  on Form 10-Q  for the period ended March 31, 2011. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
2. Transgenomic, Inc. Acquires Exclusive Worldwide License to Predictive Markers for Cancer Drug Response
3. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
4. Transgenomic Reports First Quarter Financial Results
5. Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today
6. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
7. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
8. Rosetta Genomics Announces Issuance of Additional U.S. Patent
9. Transgenomic, Inc. Presents Its Latest Technology at the BIT Life Sciences World DNA and Genome Day Conference, Dalian, China
10. Transgenomic, Inc. Expands SURVEYOR® Scan Product Line With BRAF and PIK3CA Mutation Detection Kits
11. Everist Genomics Announces Worldwide Availability of OncoDefender™-CRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... as senior vice president of sales, announced Andrea Heslin Smiley , VMS president ... business development and sales team, exploring new opportunities for VMS to empower patients and ... ... ... ...
(Date:5/24/2016)... Open Access Journal Focusing ... Elsevier , a world-leading provider of scientific, ... the launch of Clinical Neurophysiology ... on clinical practice issues in clinical neurophysiology. The journal ... values and didactic reviews. It is an official journal ...
(Date:5/23/2016)... 2016 Global Paclitaxel Market 2016 ... 12 companies and the Paclitaxel analysis in this study ... industry and its players. This is the ... details the current state of the industry while providing ... applications and industry chain structure. The Paclitaxel market analysis ...
Breaking Medicine Technology:
(Date:5/24/2016)... Irvine, CA — , ... ... the appointment of three new members of its Advisory Board. ... Chico and Sarah Kusch. “All three of them embody the mission ... team. We are very fortunate to have them as we continue ...
(Date:5/24/2016)... ... May 24, 2016 , ... Boyd Industries, a leading supplier of ... a groundbreaking new product for pediatric dentistry , at AAPD 2016, the annual ... TX May 26-29. The Concealed Delivery Unit keeps dental hand pieces and other anxiety-provoking ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research Water Life ... and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, ... 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her ...
Breaking Medicine News(10 mins):